Poly(L-glutamic acid)--anticancer drug conjugates.
Chemotherapy has had limited success in the treatment of cancer over the years, due, in part, to the untoward toxicity of the therapeutic agent to normal cells. The design of tailor-made polymer conjugates provides a synthetic approach that can overcome some of the problems. Several synthetic polymer-based anticancer drug conjugates have entered clinical studies. This report reviews the chemistry, physicochemical properties, and therapeutic applications in cancer therapy of polymeric chemotherapeutic agents based on poly(L-glutamic acid). Targeted delivery of anticancer agents using poly(L-glutamic acid) as the drug carrier is also discussed with emphasis on the design of innovative polymeric constructs.
Li
Chun
C
Department of Experimental Diagnostic Imaging, Box 59, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. cli@di.mdacc.tmc.edu
D018943:Anthracyclines / Q000008:administration & dosage / Q000627:therapeutic use; D000963:Antimetabolites / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004247:DNA / Q000378:metabolism; D004337:Drug Carriers; D016503:Drug Delivery Systems; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D011099:Polyglutamic Acid / Q000138:chemical synthesis / Q000493:pharmacokinetics
D018943:Anthracyclines; D000963:Antimetabolites; D000970:Antineoplastic Agents; D004337:Drug Carriers; D011099:Polyglutamic Acid; D004247:DNA; D017239:Paclitaxel; D002166:Camptothecin